Foralumab
Monoclonal antibody
Also known as NI-0401, TZLS-401
Evidence outlook
Multiple Sclerosis: topline reported 2026-11-02
The sponsor reported topline results on 2026-11-02 (Phase 2a INFORM-MS met its dual primary endpoints). The announcement is listed under Regulatory events.
Also in development:Secondary Progressive Multiple Sclerosis · Phase 2Amyotrophic Lateral Sclerosis · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06292923 NCT06292923 · Multiple Sclerosis Registry: NCT06292923 | 2 | The number of patients with adverse event (AE) reports. (Throughout the study, an average of 12 weeks (3 months).); Changes in the Total Nasal Symptom Score (TNSS). (TNSS is performed during the Screening Visit and during the Treatment Period at the first visit of Cycle 1, Cycle 2, Cycle 3, and Cycle 4 (each Cycle is 3 weeks).); Change from baseline for [18F]PBR06-positron emission tomography (PET) scans for microglial activation after 12 weeks (3 months) of study treatment. (Subjects will undergo PET imaging prior to Week 1 (i.e., prior to dosing) and after Week 12 (after Cycle 4 at the PET sub-study site).) 2026-09-17 | Results not posted; external-source review pending | not yet graded | link ↗ |
View 1 more trial
NCT06890923 NCT06890923 · Multiple Sclerosis Registry: NCT06890923 | 2 | Safety and Tolerability (Day 1 vs Day 169 (end of study)); Change in Baseline (Day 1 vs Day 169 (or termination)); Safety and Tolerability (Day 1 vs Day 169 (or termination)); Safety and Tolerability (Day 1 vs Day 169 (or termination)]); Safety and Tolerability (Day 1 vs Day 169 (or termination)); Safety and Tolerability (Day 1 vs Day 169 (or termination)) 2026-04-30 | In progress: primary completion was expected 30 Apr 2026; results not posted | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (2)
What this study did
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Amyotrophic Lateral Sclerosis: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Foralumab: this drug | Phase 2 | Monoclonal antibody | CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Edaravone (Radicava ORS) | Approved | Small molecule | Reactive oxygen species (ROS) | Weak signal | Featured results are safety only in this race | |
| Tofersen (Qalsody) | Approved | RNA / oligonucleotide | SOD1 | Partial signal | No reviewed efficacy summary in this indication | |
| Masitinib | Phase 3 | Small molecule | KIT (c-Kit), also PDGFR and Lyn/Fyn kinases | not yet graded | No reviewed efficacy summary in this indication | |
| Ulefnersen | Phase 3 | RNA / oligonucleotide | FUS | Reliable signal | NCT04768972: FUSION (NCT04768972): ulefnersen met its primary endpoint, a joint rank (win-ratio style) analysis of time to death/permanent ventilation, time to rescue, and change in ALSFRS-R score to Day 505 vs placebo; p=0.0005. | |
| CB03-154 | Phase 2/3 | Small molecule | KCNQ2/3 (Kv7.2/7.3) potassium channel (opener) | not yet graded | No reviewed efficacy summary in this indication | |
| CNM-Au8 | Phase 2/3 | Nanoparticle | mitochondrial energy metabolism | not yet graded | No reviewed efficacy summary in this indication | |
| Ibudilast | Phase 2/3 | Small molecule | PDE4 and PDE10; macrophage migration inhibitory factor (MIF) | not yet graded | No reviewed efficacy summary in this indication | |
| Tazbentetol (SPG302) | Phase 2/3 | Small molecule | Dendritic spine density | Weak signal | Featured results are safety only in this race | |
| Dazucorilant | Phase 2 | Small molecule | Glucocorticoid receptor | not yet graded | No reviewed efficacy summary in this indication | |
| ALN-SOD | Phase 1/2 | RNA / oligonucleotide | SOD1 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Foralumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent